Cervical cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Pathologically proven primary cervical cancer IIB-IVA with squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma(FIGO 2018); 2. Patients who have not received any previous radiation, chemotherapy or surgery; 3. Female aged 18-70 years old; 4. Adequate liver functions: Total bilirubin /= 80 mL/min; 6. Adequate hematologic functions: Absolute neutrophil count (ANC) >/= 2,000/mcl; Platelets >/= 100,000/mcl; Hemoglobin >/= 9g/dL; 7. Patients with other severe disease (heart, lung); 8. Performance status 0, 1, 2 (refer to the appendix); 9. Patients must have signed an approved informed consent and authorization permitting release of personal health information.
Exclusion criteria
Exclusion criteria: 1. Patients with septicemia or severe infection; 2. Patients with intestinal obstruction or gastrointestinal bleeding; 3. Patients in pregnant or lactation period; 4. Patients whose circumstances do not permit completion of the study or the required follow-up; 5. Patients with renal abnormalities requiring modification of radiation field (pelvic kidney, renal transplant, etc.); 6. Acquiring other experimental therapy (in the period of other trail treatment); 7. Patients with a history of other invasive malignancies before enrollment; 8. Distant metastasis was found before treatment; 9. Known allergy to chemotherapy drugs that may be used; 10. Factors affecting drug administration, distribution, metabolism and excretion, such as mental abnormalities, central nervous system abnormalities, chronic diarrhea, ascites, pleural effusion, etc; 11. Disagree to sign the informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PSF;OS;Treatment Response Rate;Safety and Toxicities Assessment; | — |
Countries
China
Contacts
Department of Radiation Oncology, The First Affiliated Hospital of Sun Yat-sen University